Modulating the Immune SystemA clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with chronic inflammatory diseases, viral infections, and cancer.
Fighting Inflammatory DiseasesAbivax’s lead candidate ABX464, a potent anti-inflammatory agent, is being tested in a Phase 2b clinical trial for its potential to bring clinical benefit to patients with ulcerative colitis, and potentially other inflammatory indications.
Tackling CancerA small molecule agonist of invariant Natural Killer T-Cells (iNKT) is currently being tested in a Phase 1/2 clinical trial for treatment of hepatocellular carcinoma (HCC).
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat chronic inflammatory diseases, viral diseases, and cancer.
Its lead clinical candidate, ABX464, has demonstrated strong clinical anti-inflammatory effects in ulcerative colitis.
With four programs in clinical testing, a trial in Crohn’s disease to start and three projects in research and preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.
News & Events
Abivax SA has been listed on the Paris stock exchange since June 26, 2015.